Investor Alert: Pomerantz Law Firm Investigates Claims Against Ventyx Biosciences, Inc. (VTYX)
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is currently investigating claims on behalf of investors in Ventyx Biosciences, Inc. (NASDAQ: VTYX). This investigation focuses on whether Ventyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Investors are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980 for more information.
Details of the Investigation
The investigation arises following a press release from Ventyx on December 2, 2025, which provided an update regarding its ongoing Phase 2 study of VTX2735 in patients suffering from recurrent pericarditis (RP). In this release, the Company’s Chief Executive Officer stated, “We are… revising our guidance for topline data release from the interim analysis of the Phase 2 RP trial to Q1 2026.”
He elaborated that this change would allow Ventyx to introduce dose-ranging studies with their new once-daily formulation in the current Phase 2 study, alongside expanding into Canada, the EU, and the UK. This strategy is projected to accelerate Phase 3 timelines.
Impact on Stock Performance
Following the announcement, Ventyx's stock price sharply declined by $1.44 per share, a drop of 15.35%, closing at $7.94 per share on December 2, 2025. This decline in stock value underscores the potential impact of the investigation on the company's shareholders and its reputation in the market.
About Pomerantz LLP
Pomerantz LLP, with offices located in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as a leader in corporate, securities, and antitrust class litigation. Established by the late Abraham L. Pomerantz, known as the dean of the class action bar, the firm has a longstanding tradition of fighting for the rights of victims of securities fraud and corporate misconduct. Over its 85-year history, Pomerantz has successfully recovered significant damages for various class members.
Contact Information
Investors who believe they may have been affected by Ventyx Biosciences, Inc.'s actions are urged to contact:
- Name: Danielle Peyton
- Firm: Pomerantz LLP
- Email: dpeyton@pomlaw.com
- Phone: 646-581-9980 ext. 7980
For additional details regarding this investigation, interested parties can visit www.pomlaw.com. Please note that attorney advertising and prior results do not guarantee similar outcomes.